Crispr Therapeutics shares tumble after significant earnings miss
UBS upgraded Beijing Huafeng Test & Control Tech (688200:CH) from Neutral to Buy on Monday, raising its price target to RMB165.00 from RMB105.00. The upgrade follows a recent pullback in the stock price, with UBS citing a projected 26% earnings compound annual growth rate from 2026 to 2028 that it believes is not reflected in the current valuation of 28 times 2026 estimated price-to-earnings.
The firm expressed increased optimism about demand for Huafeng’s existing products, particularly its traditional analog integrated circuit testers (STS8200/STS8300), driven by accelerating localization and improving end-market conditions. UBS also noted faster-than-expected ramp-up of the company’s new high-end system-on-a-chip tester, the STS8600.
Based on these factors, UBS raised its 2026-2028 earnings per share estimates by 20-28%, projecting higher revenue and improved profitability. The new estimates stand 9% and 6% above Wind consensus forecasts for 2026 and 2027, respectively.
Huafeng is currently trading around one standard deviation below its historical average, despite delivering a 24% earnings compound annual growth rate from 2016 to 2024. UBS noted that while the stock trades in line with analog integrated circuit fabless companies, it deserves a higher valuation given its breakthrough in high-end system-on-a-chip testing technology.
UBS identified potential catalysts for the stock, including better-than-expected second-quarter results or stronger shipments of the STS8600 tester. The firm’s new price target represents significant upside from current trading levels.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.